104 related articles for article (PubMed ID: 26615920)
21. Targeted Proteomics as a Tool for Quantifying Urine-Based Biomarkers.
Mohan SV; Nayakanti DS; Sathe G; George IA; Gowda H; Kumar P
Methods Mol Biol; 2020; 2051():277-295. PubMed ID: 31552634
[TBL] [Abstract][Full Text] [Related]
22. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization.
Wu H; Liu T; Ma C; Xue R; Deng C; Zeng H; Shen X
Anal Bioanal Chem; 2011 Aug; 401(2):635-46. PubMed ID: 21626193
[TBL] [Abstract][Full Text] [Related]
23. Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer.
Davalieva K; Kostovska IM; Kiprijanovska S; Markoska K; Kubelka-Sabit K; Filipovski V; Stavridis S; Stankov O; Komina S; Petrusevska G; Polenakovic M
Prostate; 2015 Oct; 75(14):1586-600. PubMed ID: 26074449
[TBL] [Abstract][Full Text] [Related]
24. Differences in urinary proteins related to surgical margin status after radical prostatectomy.
Heger Z; Michalek P; Guran R; Cernei N; Duskova K; Vesely S; Anyz J; Stepankova O; Zitka O; Adam V; Kizek R
Oncol Rep; 2015 Dec; 34(6):3247-55. PubMed ID: 26503549
[TBL] [Abstract][Full Text] [Related]
25. Discovery of colorectal cancer biomarker candidates by membrane proteomic analysis and subsequent verification using selected reaction monitoring (SRM) and tissue microarray (TMA) analysis.
Kume H; Muraoka S; Kuga T; Adachi J; Narumi R; Watanabe S; Kuwano M; Kodera Y; Matsushita K; Fukuoka J; Masuda T; Ishihama Y; Matsubara H; Nomura F; Tomonaga T
Mol Cell Proteomics; 2014 Jun; 13(6):1471-84. PubMed ID: 24687888
[TBL] [Abstract][Full Text] [Related]
26. Quantification of proteins in urine samples using targeted mass spectrometry methods.
Khristenko N; Domon B
Methods Mol Biol; 2015; 1243():207-20. PubMed ID: 25384748
[TBL] [Abstract][Full Text] [Related]
27. Discovery of biomarkers for gastric cancer: a proteomics approach.
Lin LL; Huang HC; Juan HF
J Proteomics; 2012 Jun; 75(11):3081-97. PubMed ID: 22498886
[TBL] [Abstract][Full Text] [Related]
28. D-PCa-2: a novel transcript highly overexpressed in human prostate and prostate cancer.
Weigle B; Kiessling A; Ebner R; Fuessel S; Temme A; Meye A; Schmitz M; Rieger MA; Ockert D; Wirth MP; Rieber EP
Int J Cancer; 2004 May; 109(6):882-92. PubMed ID: 15027122
[TBL] [Abstract][Full Text] [Related]
29. Recent progress in urinary proteome analysis for prostate cancer diagnosis and management.
Frantzi M; Latosinska A; Merseburger AS; Mischak H
Expert Rev Mol Diagn; 2015; 15(12):1539-54. PubMed ID: 26491818
[TBL] [Abstract][Full Text] [Related]
30. Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples.
Martinez-Garcia E; Lesur A; Devis L; Campos A; Cabrera S; van Oostrum J; Matias-Guiu X; Gil-Moreno A; Reventos J; Colas E; Domon B
Oncotarget; 2016 Aug; 7(33):53102-53115. PubMed ID: 27447978
[TBL] [Abstract][Full Text] [Related]
31. EN2 in Prostate Cancer.
McGrath SE; Michael A; Morgan R; Pandha H
Adv Clin Chem; 2015; 71():47-76. PubMed ID: 26411411
[TBL] [Abstract][Full Text] [Related]
32. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
33. Prognostic accuracy of prostate health index and urinary prostate cancer antigen 3 in predicting pathologic features after radical prostatectomy.
Vlaeminck-Guillem V
Urol Oncol; 2015 Nov; 33(11):498. PubMed ID: 26116413
[No Abstract] [Full Text] [Related]
34. Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study.
Struck-Lewicka W; Kordalewska M; Bujak R; Yumba Mpanga A; Markuszewski M; Jacyna J; Matuszewski M; Kaliszan R; Markuszewski MJ
J Pharm Biomed Anal; 2015; 111():351-61. PubMed ID: 25684700
[TBL] [Abstract][Full Text] [Related]
35. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
36. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics.
Hüttenhain R; Soste M; Selevsek N; Röst H; Sethi A; Carapito C; Farrah T; Deutsch EW; Kusebauch U; Moritz RL; Niméus-Malmström E; Rinner O; Aebersold R
Sci Transl Med; 2012 Jul; 4(142):142ra94. PubMed ID: 22786679
[TBL] [Abstract][Full Text] [Related]
37. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
[TBL] [Abstract][Full Text] [Related]
38. Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers.
Mengual L; Ars E; Lozano JJ; Burset M; Izquierdo L; Ingelmo-Torres M; Gaya JM; Algaba F; Villavicencio H; Ribal MJ; Alcaraz A
Actas Urol Esp; 2014 Apr; 38(3):143-9. PubMed ID: 24206626
[TBL] [Abstract][Full Text] [Related]
39. A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus.
Kaushal A; Myers SA; Dong Y; Lai J; Tan OL; Bui LT; Hunt ML; Digby MR; Samaratunga H; Gardiner RA; Clements JA; Hooper JD
Prostate; 2008 Mar; 68(4):381-99. PubMed ID: 18196551
[TBL] [Abstract][Full Text] [Related]
40. Urinary markers for prostate cancer.
Downes MR; Byrne JC; Pennington SR; Dunn MJ; Fitzpatrick JM; Watson RW
BJU Int; 2007 Feb; 99(2):263-8. PubMed ID: 17092277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
